Higher Use of Any Rx Medications Seen Years Before IBD Diagnosis
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 19, 2024 -- Individuals with inflammatory bowel disease (IBD) universally show increased prescription medication use years before diagnosis, according to a study published in the December issue of the American Journal of Gastroenterology.
Linéa Bonfils, M.D., from Aalborg University in Copenhagen, Denmark, and colleagues compared use of any prescription medication between individuals with and without IBD in a 10-year period preceding diagnosis. The analysis included 29,219 individuals diagnosed with IBD in Denmark between 2005 and 2018 and 292,190 matched, IBD-free individuals.
The researchers found that the IBD group had a universally increased use of any prescription medications versus the matched controls before IBD diagnosis. For 12 of 14 Anatomical Therapeutic Chemical main groups of medication, the proportion of users was 1.1-fold to 1.8-fold higher in the IBD population 10 years before diagnosis. Results were consistent across age, sex, and IBD subtypes, but were most pronounced for Crohn disease (CD). The IBD population had a steep increase in medication use for several organ systems two years before diagnosis. The CD population showed 2.7 times more users of immunosuppressants, 2.3 times more users of antianemic preparations, and 1.9 times more users of both analgesics and psycholeptics than the matched controls 10 years before diagnosis.
"Our findings demonstrate universally increased medication use years before IBD, especially CD, diagnosis and indicates multiorgan involvement in IBD," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 -- For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 -- There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory...
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.